WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced that the Company will host a conference call
at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's
financial results for the three-month period ended September 30, 2015.
Management also will provide an update on the Company.
To access the live call by phone, dial 913-905-3226; the conference ID
is 9613638. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through November 10, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells. The Company utilizes
its ADC technology with its antibodies to create ImmunoGen product
candidates and also out-licenses limited rights to use its technology to
other companies. Roche's Kadcyla® is the first marketed
product with ImmunoGen's ADC technology. More information about the
Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151013005239/en/
For Investors & Media:
ImmunoGen, Inc.
Carol Hausner,
781-895-0600
info@immunogen.com
Source: ImmunoGen, Inc.
News Provided by Acquire Media